IONIQ Sciences Awarded Patent by Canadian Intellectual Property Office
IONIQ Sciences has received a new Canadian Patent to add to our robust, growing intellectual portfolio of patents and know-how. We now have 8 company patents and 4 patent applications, with an additional 4 licensed patents. These valuable corporate assets will help ensure that our FDA breakthrough-designated IONIQ ProLung Test will be protected in numerous global markets while it provides vital information to patients with indeterminate pulmonary nodules. We have all been affected by the cold realities of cancer and at IONIQ we have decided that it does not have to be that way any longer. We’re fighting every day to catch cancer in its earliest, most treatable stages with our non-invasive Electrical Impedance Analytics (EIA) technology. As such, we’re happy to see our intellectual property continue to expand as the significance of our technology is further recognized. We’re eager to make a lasting contribution to the world by modernizing cancer detection!